BeOne Medicines
ONC
NZ$493.16
Share price
1.04%
Change (1 day)
80.09%
Change (1 year)
Categories
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.
BeOne Medicines (ONC) - Total debt
Total debt on the balance sheet as of March 2025 : NZ$1.66 Billion
According to BeOne Medicines's latest financial reports the company's total debt is NZ$1.66 Billion. A company’s total debt is the sum of all current and non-current debts.
BeOne Medicines - Total debt on balance sheet (from 2014 to 2025)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2024-12-31 | NZ$1.91 B | 30.18% |
| 2023-12-31 | NZ$1.47 B | 56.51% |
| 2022-12-31 | NZ$0.93 B | -7.59% |
| 2021-12-31 | NZ$1.01 B | 30.58% |
| 2020-12-31 | NZ$0.77 B | 89.13% |
| 2019-12-31 | NZ$0.41 B | 39.23% |
| 2018-12-31 | NZ$0.29 B | 27.53% |
| 2017-12-31 | NZ$0.23 B | 829.49% |
| 2016-12-31 | NZ$24.95 M | -17.84% |
| 2015-12-31 | NZ$30.37 M | 71.96% |
| 2014-12-31 | NZ$17.66 M | -46.96% |
| 2013-12-31 | NZ$33.29 M |
Total debt for similar companies or competitors
| Company | Total debt/th> | differencediff. | Country |
|---|---|---|---|
 Onconova Therapeutics ONTX | N/A | N/A | 🇺🇸 USA |
 OPKO Health
OPK | NZ$0.82 B | -50.55% | 🇺🇸 USA |